undamentalytics Newsletter
Sign in

Biote Corp. (BTMD) stock

Add to watchlist

Add holding +

NASDAQ: BTMD Nasdaq Pharmaceuticals Next results ~November 4, 2026

C Fundamentals grade

Biote Corp. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: our cash-flow value ($5.07) is 4.37x the share price ($1.16); a gap this wide almost always means a data problem.

Price vs value

Under review: our cash-flow value ($5.07) is 4.37x the share price ($1.16); a gap this wide almost always means a data problem. We'll show the comparison once resolved.

Biote Corp. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling2 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds40 adding, 46 cuttingOf 19 active managers that changed their stake, 10 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Biote files

Where Biote stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $184m, down 7.8% on a year earlier, a steeper fall than the 5.6% decline a quarter earlier. That puts it 33 of 34 for growth among the pharmaceuticals companies we cover. Free-cash-flow margin fell to 10.8% from 17.5% a year earlier. Operating margin narrowed to 8.0% from 17.8%. The diluted share count is up 3.3% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 4 financial-health checks.

Our model value for Biote is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 7, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Biote Corp.'s trailing-twelve-month revenue fell 7.8% year on year, with a free-cash-flow margin of 10.8%. Where it stands out: days sales outstanding of 16 days ranks 2 of 59 pharmaceuticals companies we cover. Where it lags: long-term debt as % of assets of 116.4% ranks 53 of 53 pharmaceuticals companies we cover.

Our discounted-cash-flow model values the business at ~$5.1 per share in the base case (~$2.7–$8.2 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 42.9% while net income fell 81.3%: a 38pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Biote Corp.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 4 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 7.8% over the last 12 months.
  • Margins narrowing. Operating margin is down 9.7 points on a year ago.
  • Share dilution. Diluted shares rose 3.3% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 74% and a beta of 1.2 against the S&P 500.
  • Growth easing. The growth rate is 2.2 points lower than a quarter earlier.

Latest results: FY2026 Q2

Filed August 7, 2026
Earnings per share
$0.04 against an average estimate of $0.03: beat by 18.0%
Revenue
$44m, down 9.5% on a year earlier
Share reaction
-28.2% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Guidance given
revenue $175m (2026 Guidance); adjusted EBITDA $25m (2026 Guidance)
Next report
November 4, 2026; average EPS estimate $0.04

Biote's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.8%
  • 1 week-1.7%
  • 1 month-1.7%
  • This year-56.5%
  • 1 year-60.6%
  • 5 years-88.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$184M
Operating margin
8.0%
Net margin
3.2%
EPS (TTM, diluted)
$0.16

Growth

Revenue growth
−7.8%
Change in growth rate
−2.2 pts
Share count change
+3.3%

Cash

Free cash flow (TTM)
$19.9M
FCF margin
10.8%
Stock pay % of revenue
4.5%

Earnings

Last results
August 5, 2026
Next results (est.)
November 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Guidance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Biote Corp. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: held for review: our cash-flow value ($5.07) is 4.37x the share price ($1.16); a gap this wide almost always means a data problem.

Our value per share comes from a discounted-cash-flow model of Biote Corp.'s free cash flow after stock-based pay ( $16.1M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Biote Corp. as an operating company, with every model that fits that kind of business. Cost of equity 9%: the 10-year Treasury yield (4.9%) plus a beta of 0.89 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$5.1 ~$2.7–$8.2 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. ~$2.9 ~$2.5–$5.6 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Biote Corp. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2022202320242025Now
Share price$3.73$4.94$6.18$2.60$1.13
Market value$30m$127m$212m$95m$40m
+ Net debt (− = net cash)$43m$27m$70m$79m$114m
Enterprise value$73m$154m$282m$174m$154m
Multiples
Price / sales 0.2x0.7x1.1x0.5x0.2x
Price / earnings —38.3x67.1x3.5x6.9x
Price / free cash flow —4.8x5.5x3.2x2.0x
EV / EBITDA —4.9x8.0x4.4x8.5x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

33 /100

Weak moat

How hard Biote's competitive advantage looks for rivals to wear away, judged from 5 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 5 / 20

    Net income has been a median 4.3% of total assets over 5 years.

  • Durability 4 / 20

    Operating margin has been a median 15.9%; its worst year was -40.2%.

  • Cash conversion 14 / 20

    Free cash flow was positive in 4 of 5 years, at a median 11.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (38 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $44m and EPS of $0.04 (range $0.04 to $0.04) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.35 −38% $178m −7%
Next $0.45 +29% $188m +6%

Next year's EPS estimate has moved −21.1% in 90 days, across 1 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −28.6% on 90 days ago. In the last 30 days, 0 analysts raised Biote Corp.'s forecast and 1 cut it.

Consensus EPS forecast Biote Corp., last 90 days
$0.30 $0.40 $0.50 $0.60 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.49 Current fiscal year, 60 days ago: $0.49 Current fiscal year, 30 days ago: $0.49 Current fiscal year, 7 days ago: $0.49 Current fiscal year, Now: $0.35 $0.35 Next fiscal year, 90 days ago: $0.57 Next fiscal year, 60 days ago: $0.57 Next fiscal year, 30 days ago: $0.57 Next fiscal year, 7 days ago: $0.57 Next fiscal year, Now: $0.45 $0.45

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.49$0.57
60 days ago $0.49$0.57
30 days ago $0.49$0.57
7 days ago $0.49$0.57
Now $0.35$0.45

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.03 $0.04 +18.0%
Mar 2026 $0.08 $0.08 −2.1%
Dec 2025 $0.10 $0.07 −29.8%
Sept 2025 $0.12 $0.18 +48.1%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 5, 2026
  • Revenue 2026 Guidance —
    “Revenue Above $175 million” source
  • Adjusted EBITDA 2026 Guidance — Non-GAAP
    “Adjusted EBITDA 2 Above $25 million” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Biote Corp.'s revenue by +0.9% next year and +2.5% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (-0.4%, weight 45%) and the company's own record (+2.0%, weight 55%) . How the weights are set.

Analyst recommendations

5 analysts, Oct 2026
Buy480%
Hold120%
Sell00%

Monthly trend

  1. Oct 2026415
  2. Sep 2026314

Counts of recommendations published by analysts covering Biote Corp., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
5.8%
of tradable shares
Days to cover
8.62
at average volume
Short interest, 1 month
−8%
to October 15, 2026
Held by institutions
63%
of shares
Held by insiders
19.8%
of shares
Employees
223
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −60.6%

$2.87 on October 31, 2025 to $1.13

ThenNowEffect
Revenue (last 12 months) $199m $184m −7.8%
Net margin 15.7% 3.2% −79.7%
P/E multiple 3.2x 6.9x +117.4%
Share count 35m 36m −3.2%

Biggest factor: net margin.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
BTMD−62%+32%+25%−58%−57%
Industry peers (median)−49%−14%−2%+9%−12%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
BTMD42%67%42%25%36%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
BTMD−66%−43%−40%−62%−60%
S&P 500−25%−10%−8%−19%−9%

Worst fall since April 28, 2021: 90% from May 12, 2021 to October 21, 2026. Getting back needed a 881% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.03 – $2.93
From 52-week high
−61.4%
vs 50-day average
−12.1%
vs 200-day average
−38.0%
Volatility (1 year)
75%
Beta vs S&P 500
1.18

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±14.5%
After a week
4 up, 8 down
typical move ±14.5%
After a month
6 up, 6 down
typical move ±12.6%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 −28.2% −0.4% −37.4% −31.7%
May 6, 2026 −5.4% +1.1% −8.1% +5.9%
March 11, 2026 −9.4% −1.6% −20.0% −6.5%
November 5, 2025 −0.7% −0.7% −7.7% −10.8%
August 6, 2025 −30.0% +0.7% −26.4% −17.0%
May 7, 2025 +11.0% +1.1% +16.9% +13.6%
March 12, 2025 −25.7% −0.8% +2.2% −18.9%
November 12, 2024 +16.9% −0.3% +5.9% +13.7%
August 8, 2024 −21.2% +2.8% −13.2% −11.3%
May 7, 2024 +0.2% +0.1% −1.8% +11.1%
March 12, 2024 +11.9% +0.9% +17.3% +10.1%
January 17, 2024 −13.2% +0.3% −16.7% +1.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Biote Corp. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Biote Corp.
$180M $185M $190M $195M $200M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $184.1M Revenue (TTM), FY23 Q4: $185.4M Revenue (TTM), FY24 Q1: $187.3M Revenue (TTM), FY24 Q2: $187.2M Revenue (TTM), FY24 Q3: $193.1M Revenue (TTM), FY24 Q4: $197.2M Revenue (TTM), FY25 Q1: $199.4M Revenue (TTM), FY25 Q2: $199.1M Revenue (TTM), FY25 Q3: $195.6M Revenue (TTM), FY25 Q4: $192.2M Revenue (TTM), FY26 Q1: $188.2M Revenue (TTM), FY26 Q2: $183.5M $183.5M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $184.1M
FY23 Q4 $185.4M
FY24 Q1 $187.3M
FY24 Q2 $187.2M
FY24 Q3 $193.1M
FY24 Q4 $197.2M
FY25 Q1 $199.4M
FY25 Q2 $199.1M
FY25 Q3 $195.6M
FY25 Q4 $192.2M
FY26 Q1 $188.2M
FY26 Q2 $183.5M
Revenue growth, TTM YoY Biote Corp.
-10% 0% 10% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 16.5% Revenue growth, TTM YoY, FY23 Q4: 12.4% Revenue growth, TTM YoY, FY24 Q1: 8.5% Revenue growth, TTM YoY, FY24 Q2: 3.7% Revenue growth, TTM YoY, FY24 Q3: 4.8% Revenue growth, TTM YoY, FY24 Q4: 6.4% Revenue growth, TTM YoY, FY25 Q1: 6.4% Revenue growth, TTM YoY, FY25 Q2: 6.3% Revenue growth, TTM YoY, FY25 Q3: 1.3% Revenue growth, TTM YoY, FY25 Q4: -2.5% Revenue growth, TTM YoY, FY26 Q1: -5.6% Revenue growth, TTM YoY, FY26 Q2: -7.8% -7.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 16.5%
FY23 Q4 12.4%
FY24 Q1 8.5%
FY24 Q2 3.7%
FY24 Q3 4.8%
FY24 Q4 6.4%
FY25 Q1 6.4%
FY25 Q2 6.3%
FY25 Q3 1.3%
FY25 Q4 -2.5%
FY26 Q1 -5.6%
FY26 Q2 -7.8%
Operating margin (TTM) Biote Corp.
5% 10% 15% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 16.5% Operating margin (TTM), FY23 Q4: 15.5% Operating margin (TTM), FY24 Q1: 16.7% Operating margin (TTM), FY24 Q2: 15.9% Operating margin (TTM), FY24 Q3: 17.8% Operating margin (TTM), FY24 Q4: 16.0% Operating margin (TTM), FY25 Q1: 15.5% Operating margin (TTM), FY25 Q2: 17.8% Operating margin (TTM), FY25 Q3: 16.1% Operating margin (TTM), FY25 Q4: 18.5% Operating margin (TTM), FY26 Q1: 15.4% Operating margin (TTM), FY26 Q2: 8.0% 8.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 16.5%
FY23 Q4 15.5%
FY24 Q1 16.7%
FY24 Q2 15.9%
FY24 Q3 17.8%
FY24 Q4 16.0%
FY25 Q1 15.5%
FY25 Q2 17.8%
FY25 Q3 16.1%
FY25 Q4 18.5%
FY26 Q1 15.4%
FY26 Q2 8.0%
FCF margin (TTM) Biote Corp.
10% 15% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 13.8% FCF margin (TTM), FY23 Q4: 14.3% FCF margin (TTM), FY24 Q1: 10.8% FCF margin (TTM), FY24 Q2: 11.2% FCF margin (TTM), FY24 Q3: 18.2% FCF margin (TTM), FY24 Q4: 19.7% FCF margin (TTM), FY25 Q1: 18.5% FCF margin (TTM), FY25 Q2: 17.5% FCF margin (TTM), FY25 Q3: 17.6% FCF margin (TTM), FY25 Q4: 15.7% FCF margin (TTM), FY26 Q1: 15.3% FCF margin (TTM), FY26 Q2: 10.8% 10.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 13.8%
FY23 Q4 14.3%
FY24 Q1 10.8%
FY24 Q2 11.2%
FY24 Q3 18.2%
FY24 Q4 19.7%
FY25 Q1 18.5%
FY25 Q2 17.5%
FY25 Q3 17.6%
FY25 Q4 15.7%
FY26 Q1 15.3%
FY26 Q2 10.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Biote took in during FY2025, followed through to profit: what it cost to make, what went on running the business, and what was left after tax.

  1. Revenue $192M
  2. Selling, general and admin $102M · 53.0%
  3. Other operating costs $54.9M · 28.5%
  4. Operating income $35.6M · 18.5%
  5. Income tax $6M · 3.1%
  6. Interest and other $2.5M · 1.3%
  7. Net income $27M · 14.1%

Shares of revenue. Source: Biote's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 139 165 185 197 192 184
EBITDA 36 −59 32 35 39 18
Operating income 35 −61 29 32 36 15
Net income 11 −1 3 3 27 6
Diluted EPS — −$0.12 $0.13 $0.09 $0.74 $0.16
Growth (year on year)
Revenue — +18.3% +12.4% +6.4% −2.5% −7.8%
EBITDA — −262.7% — +11.2% +11.5% −52.3%
Operating income — −275.7% — +10.3% +12.5% −58.3%
Net income — −108.7% — — — −81.3%
Diluted EPS — — — — — −81.9%
Margins
EBITDA margin 25.8% −35.5% 17.1% 17.8% 20.4% 9.8%
Operating margin 24.8% −36.8% 15.5% 16.0% 18.5% 8.0%
Net margin 8.0% −0.6% 1.8% 1.6% 14.1% 3.2%
Free-cash-flow margin 23.2% −5.8% 14.3% 19.7% 15.7% 10.8%
Cash flow
Cash from operations 34 −9 27 45 35 24
Capital spending 1 0 0 6 5 4
Free cash flow 32 −9 27 39 30 20
Stock-based pay — 82 9 9 9 8
Free cash flow after stock pay — −92 17 30 21 12
Balance sheet
Cash 0 79 89 39 24 11
Total debt 38 122 116 109 103 125
Net debt (negative = net cash) 37 43 27 70 79 114
Diluted shares — 8m 26m 34m 37m 36m
Returned to shareholders
Dividends 11 13 9 5 2 1
Buybacks — — — 6 3 —
Total returned 11 13 9 10 5 1

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 4 checks passed · June 30, 2026
What it owns · $102m
Short-term assets $43mLonger-term assets $59m
What it owes, and who funded it · $160m
Short-term liabilities $30mLonger-term liabilities $130mShareholders' equity $-66m
  • Short-term assets cover short-term liabilities $43m of assets due within a year against $30m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $43m short-term assets against $130m of longer-dated liabilities.
  • More cash than debt $11m of cash against $122m of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt $24m of operating cash flow against $122m of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Biote Corp.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Dividends (TTM)
$1.2M
Diluted share count
+3.3%
year over year
Total shareholder yield
3.6%
dividends 3.6% + buybacks 0.0% of market value
Dividend payout ratio
20%
of net income paid out
Sales & admin spending
60.5%
of revenue
Days sales outstanding
16 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated BTMD OGI KMDA CRON AMRN HRTX Median
Revenue, last 12 months $184m $185m $180m $179m $176m $151m $276m
Revenue growth, last 12 months −7.8% 57.8% 12.1% 37.5% −22.3% 1.0% 9.9%
Revenue growth, 3-year average 0.5% — — 30.3% −18.3% 8.6% 5.5%
Revenue growth, latest quarter −9.5% — — 58.4% −20.4% 1.3% 6.5%
Gross margin — 34.8% 42.3% 45.9% 40.9% 70.1% 62.0%
Operating margin 8.0% −5.9% 14.5% −1.4% −18.2% −7.2% −5.9%
Operating margin, 3-year average 13.9% — 7.0% −38.9% −26.3% −13.5% −7.4%
Net margin 3.2% −9.6% 11.2% 39.1% −10.9% −22.5% −7.3%
Cash from operations / revenue 13.3% −2.9% 14.1% 33.5% 21.3% −7.7% 10.2%
Free-cash-flow margin 10.8% −9.5% 13.2% 27.8% 21.3% −8.0% 8.6%
Free-cash-flow margin, 3-year average 13.2% — 1.7% 11.1% 1.3% −47.0% 7.4%
Stock pay / revenue 4.5% 1.6% 0.5% 3.6% 4.2% 7.4% 3.6%
Change in share count 3.3% 34.0% 0.9% −2.1% 1.5% 5.9% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth -7.8% 10.0% 60 of 74
Change in growth rate Growth -2.2pp -0.3pp 45 of 74
Operating margin Profitability 8.0% -5.9% 24 of 67
Net margin Profitability 3.2% -7.3% 31 of 75
Free-cash-flow margin Cash generation 10.8% 10.1% 35 of 74
Stock pay as % of revenue Cash generation 4.5% 3.6% 43 of 69
Long-term debt as % of assets Balance sheet 116.4% 23.8% 53 of 53
Change in share count Balance sheet 3.3% 1.5% 42 of 62
Days sales outstanding Balance sheet 16 days 72 days 2 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Product Revenue $187M 97.5% ▼ 2.8%
Pellet Procedures Product Revenue $137M 73.3% ▼ 8.8%
Dietary Supplements $42.9M 22.9% ▲ 19.1%
Service Revenue $5.3M 2.8% ▲ 6.9%
Shipping Fees and Other Product Revenue $2.1M 1.2% ▲ 38.9%
Disposable Trocars Product Revenue $4.9M 2.5% ▲ 11.7%

From Biote Corp.'s 10-K filed March 13, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$24.9M
Institutions reporting
72
Shares held vs prior quarter
▼ 13.4%
Positions opened / closed
15 / 26

Top buyers and sellers, Q2 2026: 40 institutions bought and 46 sold ; the biggest buyer was Millennium Management LLC (+436K shares) and the biggest seller Blackrock, Inc (−1.4M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
325 Capital LLC $8.6M 4.5M 34.6% 0.0%
Bandera Partners LLC $3.9M 2.1M 15.7% 0.0%
Vanguard Capital Management LLC $2.1M 1.1M 8.4% ▼ 1.0%
Acadian Asset Management LLC $1.2M 625K 4.7% ▼ 10.4%
Millennium Management LLC $824,206 436K 3.3% New
Dimensional Fund Advisors LP $816,058 432K 3.3% ▼ 20.5%
Blackrock, Inc. $691,636 366K 2.8% ▼ 79.0%
Citadel Advisors LLC $569,476 301K 2.3% New
Rice Hall James & Associates, LLC $496,771 263K 2.0% ▲ 5.1%
Geode Capital Management, LLC $492,587 260K 2.0% ▼ 57.7%
Jane Street Group, LLC $478,761 253K 1.9% New
AQR Capital Management LLC $475,561 252K 1.9% ▲ 368.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Biote Corp.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $202,204 2 trades by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $202,204 net buying
Insider Date Trade Shares Price Value
Beer Marc D Executive Chairman August 11, 2026 Buy 16,000 $1.55 $24,800
Beer Marc D Executive Chairman August 10, 2026 Buy 115,950 $1.53 $177,404

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 4, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 6, 2026
  • March 11, 2026
  • November 5, 2025
  • August 6, 2025
  • May 7, 2025

Recent SEC filings

Data status

When each part of this page on Biote Corp. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Biote Corp. in brief

What does Biote Corp. do?
Biote Corp. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Biote Corp.'s stock ticker?
Biote Corp. trades under the ticker BTMD on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Biote Corp.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Biote Corp. reported revenue of $184M, 7.8% lower than a year earlier, according to its SEC filings.
What is Biote Corp.'s free cash flow?
Biote Corp.'s free-cash-flow margin is 10.8% of revenue over the trailing twelve months, ranking 35 of the 74 pharmaceuticals companies we cover.
Who are Biote Corp.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are 325 Capital LLC, Bandera Partners LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Biote Corp.'s market cap?
On November 2, 2026, Biote Corp.'s market capitalisation was about $40.3M, with a price-to-earnings ratio of 6.9 and net debt of $114M. Market figures come from third-party market data and may be delayed.
Does Biote Corp. pay a dividend?
Yes: Biote Corp. paid $1.2M in dividends over the trailing twelve months, a dividend yield of 3.61% and a payout ratio of 19.9%.
Who are Biote Corp.'s competitors?
In our Pharmaceuticals peer group, the companies closest to Biote Corp. are Organigram Global Inc., Kamada LTD, Cronos Group Inc., Amarin Corp plc\uk and Heron Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Biote Corp.'s.
Are insiders buying or selling Biote Corp. stock?
Over the last 12 months, Biote Corp.'s directors and officers reported 2 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Biote Corp.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Biote Corp. announces its own schedule.